A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.

Study Overview
=================
Brief Summary
-----------------
This study aims to describe demographics, clinical, treatment and healthcare resource utilization characteristics with a particular focus on those relating to cardiovascular disease in selected treatment intensified patients with type 2 diabetes in the real-world settings in India, Pakistan, and Thailand. The study will be based on data already recorded in participants medical record and no new tests or procedures are required as part of the study. The study will last for about 6 months and it does not affect participants current treatment.

Official Title
-----------------
A Multicentre Retrospective Study of Characterization of Treatment Intensified (Add on to Metformin) Real World Adult Population With Type 2 Diabetes Mellitus in India, Pakistan, and Thailand.

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). Male or female, age above or equal to 18 years at type 2 diabetes mellitus (T2DM) diagnosis Year of birth 1928 or later (age blow 90 years old in 2017) T2DM diagnosis in medical record on or after the date of local GLP-1 RA marketing authorization Medical records documenting prior or ongoing treatment with metformin Medical records documenting treatment with other non-metformin T2DM drugs Exclusion Criteria: Previous participation in this study. Participation is defined as having given informed consent in this study. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. Patients with any diagnosis of type 1 diabetes mellitus (T1DM)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Real world adult population with type 2 diabetes mellitus (T2DM)<br> | Other: No treatment given<br>* The study will be based on data already recorded in the medical record<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI (body mass index) | BMI will be calculated from height and weight data reported as percent of patients | 6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective) | 
| Most recent blood pressure measurement values | Reported as mmHg | 6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective) | 
| The proportion of patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA) | Will be reported as percent of patients | At Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) | 
| The proportion of patients prescribed cardiovascular disease (CVD) medications | Will be reported as percent of patients | Since the start of medical record |